People
On day two of Cowen and Company’s 39th Annual Health Care Conference, more companies shared insight into pipeline development. BioSpace rounded up a few of the stories.
Francis’ last day with Sandoz will be March 31. Francesco Balestrieri, who is currently Region Head Europe for Sandoz, has been appointed interim CEO. He will report to Vas Narasimhan, the CEO of Novartis
In the wake of the scandal caused by a Chinese researcher’s use of CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples, leading scientists called for a moratorium on heritable genome editing.
First Light Diagnostics announced the addition of Dr. Stephen Brecher to the company’s world-class, international Clinical Advisory Board.
A recent report by the U.S. Bureau of Labor Statistics and CBRE Research identified Seattle—which happens to be the BioSpace Bio Forest Hotbed—as the fastest-growing life science market in the top 10 from 2014 to 2017, with a greater than 17-percent growth.
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, announces that it has appointed Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.
National Cancer Institute Director Norman “Ned” Sharpless will take over the role as acting commissioner of the FDA while the White House seeks a permanent replacement for the outgoing Scott Gottlieb.
With Cowen & Company’s 39th Annual Health Care Conference going on in Boston this week, a lot of stories in the biopharma industry are coming out. Here are a few highlights.
Shares of Zafgen are down more than 22 percent in premarket trading after the company announced Monday that it was suspending plans to develop a treatment for Prader-Willi syndrome.
The president’s proposed spending plan cuts $4.5 to $5.5 billion from the current budget of the National Institutes of Health, about an 11 percent decrease from 2019.
PRESS RELEASES